Drug intelligence / Profile preview

OBT822

Development stage: Preclinical
Lead developer: Oxford BioTherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

OBT822 is a bispecific antibody developed by Oxford BioTherapeutics (OBT). It is being investigated in a clinical collaboration with Agenus, where it is combined with Agenus's immunomodulators, such as botensilimab or balstilimab, for the treatment of solid tumors. This partnership aims to explore new immunotherapy combinations and leverage complementary mechanisms to overcome treatment resistance in cancer.

Beyond the preview

Go deeper on OBT822.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBT822.

Explore the full profile